MA41139B1 - Combinaison pharmaceutique comprenant du ponesimod et son utilisation dans le traitement de la sclérose en plaque - Google Patents
Combinaison pharmaceutique comprenant du ponesimod et son utilisation dans le traitement de la sclérose en plaqueInfo
- Publication number
- MA41139B1 MA41139B1 MA41139A MA41139A MA41139B1 MA 41139 B1 MA41139 B1 MA 41139B1 MA 41139 A MA41139 A MA 41139A MA 41139 A MA41139 A MA 41139A MA 41139 B1 MA41139 B1 MA 41139B1
- Authority
- MA
- Morocco
- Prior art keywords
- pharmaceutical combination
- ponesimod
- treatment
- multiple sclerosis
- combination including
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Otolaryngology (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
Abstract
La présente invention concerne une combinaison pharmaceutique comportant un premier principe actif qui est (R)-5- [3-chloro-4-(2,3-dihydroxy-propoxy)-benz [Z] ylidène]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one ou son sel pharmaceutiquement acceptable et un deuxième principe actif qui est choisi dans le groupe constitué de fumarate de méthyle, du fumarate de diméthyle, de (N, N-diéthylcarbamoyle) méthyle méthyle (2E) but-2-ène-1,4-dioate, et de 2-(2,5-dioxopyrrolidin-1-yl) éthyle méthyle but-2-ène-1,4-dioate, ou un sel pharmaceutiquement acceptable de celui-ci.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2014077469 | 2014-12-11 | ||
| PCT/EP2015/079311 WO2016092042A1 (fr) | 2014-12-11 | 2015-12-10 | Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1 |
| EP15808184.4A EP3229794B1 (fr) | 2014-12-11 | 2015-12-10 | Combinaison pharmaceutique comprenant du ponesimod et son utilisation dans le traitement de la sclérose en plaque |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA41139A MA41139A (fr) | 2017-10-17 |
| MA41139B1 true MA41139B1 (fr) | 2026-02-27 |
Family
ID=54848562
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA41139A MA41139B1 (fr) | 2014-12-11 | 2015-12-09 | Combinaison pharmaceutique comprenant du ponesimod et son utilisation dans le traitement de la sclérose en plaque |
| MA41481A MA41481B1 (fr) | 2014-12-11 | 2015-12-10 | Régime posologique pour ponesimod, un agoniste du récepteur s1p1 sélectif |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA41481A MA41481B1 (fr) | 2014-12-11 | 2015-12-10 | Régime posologique pour ponesimod, un agoniste du récepteur s1p1 sélectif |
Country Status (25)
| Country | Link |
|---|---|
| US (6) | US10245253B2 (fr) |
| EP (2) | EP3229794B1 (fr) |
| JP (3) | JP6437119B2 (fr) |
| KR (3) | KR101996245B1 (fr) |
| CN (1) | CN106999462B (fr) |
| AU (1) | AU2015359306B2 (fr) |
| BR (1) | BR112017012396B1 (fr) |
| CA (1) | CA2964616C (fr) |
| CL (1) | CL2017001479A1 (fr) |
| CY (1) | CY2022011I2 (fr) |
| EA (2) | EA202290017A1 (fr) |
| ES (1) | ES3053660T3 (fr) |
| HK (1) | HK1245106A1 (fr) |
| HR (1) | HRP20251463T1 (fr) |
| IL (2) | IL252701B (fr) |
| MA (2) | MA41139B1 (fr) |
| MX (2) | MX2021005516A (fr) |
| PH (1) | PH12017501060B1 (fr) |
| PL (1) | PL3229794T3 (fr) |
| RS (1) | RS67683B1 (fr) |
| SA (1) | SA517381489B1 (fr) |
| SG (1) | SG11201704569SA (fr) |
| SM (1) | SMT202500469T1 (fr) |
| UA (1) | UA122063C2 (fr) |
| WO (1) | WO2016092042A1 (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009115954A1 (fr) | 2008-03-17 | 2009-09-24 | Actelion Pharmaceuticals Ltd | Régime de dosage pour un agoniste sélectif du récepteur s1p<sb>1</sb> |
| MA41139B1 (fr) * | 2014-12-11 | 2026-02-27 | Laboratoires Juvise Pharmaceuticals | Combinaison pharmaceutique comprenant du ponesimod et son utilisation dans le traitement de la sclérose en plaque |
| DK3256125T3 (da) | 2014-12-11 | 2022-03-21 | Actelion Pharmaceuticals Ltd | Doseringsregimen for ponesimod, en selektiv s1p1-receptoragonist |
| JOP20190207A1 (ar) | 2017-03-14 | 2019-09-10 | Actelion Pharmaceuticals Ltd | تركيبة صيدلانية تشتمل على بونيسيمود |
| US11014897B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof |
| US11014940B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Thiazolidinone and oxazolidinone compounds and formulations |
| US11186556B1 (en) | 2018-10-16 | 2021-11-30 | Celgene Corporation | Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof |
| US11013723B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms of a thiazolidinone compound, compositions and methods of use thereof |
| EP4146190A2 (fr) * | 2020-05-06 | 2023-03-15 | Imcyse SA | Polythérapie pour le traitement de maladies associées au fumarate |
| US20240368065A1 (en) * | 2021-04-23 | 2024-11-07 | Helmholtz-Zentrum für Infektionsforschung GmbH | Citraconic acid and derivatives thereof for use as a medicament |
| KR20230120768A (ko) | 2022-02-10 | 2023-08-17 | 하나 영농조합법인 | 양념 핫소스와 그 제조방법 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4959389A (en) | 1987-10-19 | 1990-09-25 | Speiser Peter P | Pharmaceutical preparation for the treatment of psoriatic arthritis |
| DE19853487A1 (de) | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
| GB0217152D0 (en) | 2002-07-24 | 2002-09-04 | Novartis Ag | Organic compounds |
| JP2009513523A (ja) | 2003-07-08 | 2009-04-02 | ノバルティス アクチエンゲゼルシャフト | ベンゼンスルホニルアミノ化合物およびそれらを含む医薬組成物 |
| US7435828B2 (en) | 2003-11-21 | 2008-10-14 | Actelion Pharmaceuticals Ltd. | Thiazolidin-4-one derivatives |
| USRE43833E1 (en) | 2003-11-21 | 2012-11-27 | Actelion Pharmaceuticals Ltd. | Thiazolidin-4-one derivatives |
| US7718704B2 (en) | 2004-02-24 | 2010-05-18 | Irm Llc | Immunosuppressant compounds and compositions |
| SI2801354T1 (sl) * | 2004-10-08 | 2017-07-31 | Forward Pharma A/S | Farmacevtske sestave z nadzorovanim sproščanjem, ki zajemajo ester fumarne kisline |
| SG187468A1 (en) | 2004-11-29 | 2013-02-28 | Novartis Ag | Dosage regimen of an s1p receptor agonist |
| US7879821B2 (en) | 2006-01-26 | 2011-02-01 | University Of Medicine And Dentistry Of New Jersey | Method for modulating inflammatory responses by altering plasma lipid levels |
| MX2009005048A (es) | 2006-11-23 | 2009-05-25 | Actelion Pharmaceuticals Ltd | Nuevo proceso para la preparacion de derivados de 2-imino-tiazolidin-4-ona. |
| US8912340B2 (en) | 2006-11-23 | 2014-12-16 | Actelion Pharmaceuticals Ltd. | Process for the preparation of 2-imino-thiazolidin-4-one derivatives |
| DK2653873T3 (da) | 2007-02-08 | 2022-07-25 | Biogen Ma Inc | Sammensætninger og anvendelser til behandling af multipel sklerose |
| WO2009115954A1 (fr) | 2008-03-17 | 2009-09-24 | Actelion Pharmaceuticals Ltd | Régime de dosage pour un agoniste sélectif du récepteur s1p<sb>1</sb> |
| DK2334378T3 (da) * | 2008-08-19 | 2014-07-07 | Xenoport Inc | Prodrugs af methylhydrogenfumarat, farmaceutiske sammensætninger deraf og fremgangsmåder til anvendelse |
| EP2177521A1 (fr) | 2008-10-14 | 2010-04-21 | Almirall, S.A. | Nouveaux dérivés de 2-amidothiadiazole |
| GB0819182D0 (en) | 2008-10-20 | 2008-11-26 | Actelion Pharmaceuticals Ltd | Crystalline forms |
| WO2010065760A1 (fr) | 2008-12-04 | 2010-06-10 | Exelixis, Inc. | Dérivés d’imidazo[1,2a]pyridine, leur emploi en tant qu'agonistes de s1p1 et leurs méthodes de production |
| PL2379067T3 (pl) | 2008-12-22 | 2016-02-29 | Novartis Ag | Schemat dawkowania fingolimodu w leczeniu stwardnienia rozsianego |
| WO2010072703A1 (fr) | 2008-12-22 | 2010-07-01 | Novartis Ag | Régime posologique d'un agoniste du récepteur s1p |
| EP2202232A1 (fr) | 2008-12-26 | 2010-06-30 | Laboratorios Almirall, S.A. | Dérivés du 1,2,4-oxadiazole et leur application thérapeutique |
| KR101699912B1 (ko) | 2009-01-09 | 2017-01-25 | 포워드 파마 에이/에스 | 1종 이상의 푸마르산 에스테르를 침식 매트릭스에 함유하는 제제 |
| EP2210890A1 (fr) | 2009-01-19 | 2010-07-28 | Almirall, S.A. | Dérivés d'oxadiazoles en tant qu'agonistes du récepteur S1P1 |
| DE102010048788A1 (de) | 2009-02-13 | 2011-05-19 | Amw Gmbh | Transdermales System mit Immunmodulator |
| DE102009008851A1 (de) | 2009-02-13 | 2010-08-19 | Amw Gmbh | Transdermales System mit Immunmodulator |
| US20100260755A1 (en) | 2009-04-09 | 2010-10-14 | Medicinova, Inc. | Ibudilast and immunomodulators combination |
| EP2305660A1 (fr) | 2009-09-25 | 2011-04-06 | Almirall, S.A. | Nouveaux dérivés de thiadiazole |
| EP2507633A1 (fr) | 2009-12-01 | 2012-10-10 | Metanomics Health GmbH | Moyens et méthodes permettant de diagnostiquer la sclérose en plaques |
| EP2343287A1 (fr) | 2009-12-10 | 2011-07-13 | Almirall, S.A. | Nouveaux dérivés de 2-aminothiadiazole |
| DE102010026879A1 (de) | 2010-02-11 | 2011-08-11 | AMW GmbH, 83627 | Transdermales System mit Immunmodulator |
| EP2366702A1 (fr) | 2010-03-18 | 2011-09-21 | Almirall, S.A. | Nouveaux dérivés d'oxadiazole |
| EP2390252A1 (fr) | 2010-05-19 | 2011-11-30 | Almirall, S.A. | Nouveaux dérivés de pyrazole |
| EP2455080A1 (fr) | 2010-11-23 | 2012-05-23 | Almirall, S.A. | Agonistes de récepteur S1P1 à utiliser dans le traitement de la sclérose en plaques |
| EP2713724A4 (fr) | 2011-05-26 | 2015-03-11 | Biogen Idec Inc | Méthodes de traitement de la sclérose en plaques et de conservation et/ou d'augmentation de la teneur en myéline |
| EP2715361A1 (fr) | 2011-05-31 | 2014-04-09 | Metanomics Health GmbH | Méthodes pour diagnostiquer la sclérose en plaques |
| CN113244185A (zh) | 2012-02-07 | 2021-08-13 | 比奥根玛公司 | 含有富马酸二甲酯的药物组合物 |
| US20130259856A1 (en) | 2012-03-27 | 2013-10-03 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate |
| US20130314669A1 (en) | 2012-05-24 | 2013-11-28 | Hadasit Medical Research Services And Development Ltd. | Method and system for assessing visual disorder |
| TWI631097B (zh) | 2012-07-27 | 2018-08-01 | 百健Ｍａ公司 | 作爲ｓ１ｐ調節劑及／或ａｔｘ調節劑之化合物 |
| EP2692343A1 (fr) | 2012-08-03 | 2014-02-05 | Forward Pharma A/S | Polythérapie pour le traitement de la sclérose en plaques |
| HK1211237A1 (en) | 2012-08-06 | 2016-05-20 | Biogen Ma Inc. | Compounds that are s1p modulating agents and/or atx modulating agents |
| US9499485B2 (en) | 2012-08-06 | 2016-11-22 | Biogen Ma Inc. | Compounds that are S1P modulating agents and/or ATX modulating agents |
| WO2014028299A1 (fr) | 2012-08-13 | 2014-02-20 | Biogen Idec Ma Inc. | Paramètres de progression de la maladie et leurs utilisations dans l'évaluation de la sclérose en plaques |
| SMT202000298T1 (it) | 2012-08-17 | 2020-07-08 | Actelion Pharmaceuticals Ltd | Processo per la produzione di (2z,5z)-5-(3-cloro-4((r)-2,3-diidrossipropossi) benziliden)-2-(propilimmino)-3-(o-tolil)tiazolidin-4-one e intermedio usato in detto processo |
| JP2015527372A (ja) | 2012-08-22 | 2015-09-17 | ゼノポート，インコーポレイティド | 副作用を低減させるモノメチルフマレートおよびそのプロドラッグの投与方法 |
| US20140348915A9 (en) * | 2012-08-22 | 2014-11-27 | Xenoport, Inc. | Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof |
| CN104870014A (zh) | 2012-10-09 | 2015-08-26 | 比奥根Ma公司 | 联合治疗及用于治疗脱髓鞘病症的用途 |
| WO2014071371A1 (fr) | 2012-11-05 | 2014-05-08 | Xenoport, Inc. | Cocristaux de méthyl(2e)but-2-ène-1,4-dioate de (n,n‑diéthylcarbamoyl)méthyle |
| CN105452213B (zh) | 2013-03-14 | 2017-09-22 | 阿尔克梅斯制药爱尔兰有限公司 | 富马酸酯前体药物及其在治疗多种疾病中的应用 |
| US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
| WO2015066515A1 (fr) | 2013-11-01 | 2015-05-07 | Receptos, Inc. | Modulateurs sélectifs des récepteurs de la sphingosine-1-phosphate et traitement combiné les utilisant |
| MA41139B1 (fr) * | 2014-12-11 | 2026-02-27 | Laboratoires Juvise Pharmaceuticals | Combinaison pharmaceutique comprenant du ponesimod et son utilisation dans le traitement de la sclérose en plaque |
| DK3256125T3 (da) | 2014-12-11 | 2022-03-21 | Actelion Pharmaceuticals Ltd | Doseringsregimen for ponesimod, en selektiv s1p1-receptoragonist |
-
2015
- 2015-12-09 MA MA41139A patent/MA41139B1/fr unknown
- 2015-12-10 UA UAA201707085A patent/UA122063C2/uk unknown
- 2015-12-10 RS RS20260077A patent/RS67683B1/sr unknown
- 2015-12-10 EA EA202290017A patent/EA202290017A1/ru unknown
- 2015-12-10 EA EA201791260A patent/EA039629B1/ru unknown
- 2015-12-10 JP JP2017531166A patent/JP6437119B2/ja active Active
- 2015-12-10 EP EP15808184.4A patent/EP3229794B1/fr active Active
- 2015-12-10 US US15/534,951 patent/US10245253B2/en active Active
- 2015-12-10 MA MA41481A patent/MA41481B1/fr unknown
- 2015-12-10 HK HK18104570.0A patent/HK1245106A1/zh unknown
- 2015-12-10 HR HRP20251463TT patent/HRP20251463T1/hr unknown
- 2015-12-10 MX MX2021005516A patent/MX2021005516A/es unknown
- 2015-12-10 EP EP25194913.7A patent/EP4620526A3/fr active Pending
- 2015-12-10 BR BR112017012396-7A patent/BR112017012396B1/pt active IP Right Grant
- 2015-12-10 ES ES15808184T patent/ES3053660T3/es active Active
- 2015-12-10 KR KR1020177019100A patent/KR101996245B1/ko active Active
- 2015-12-10 AU AU2015359306A patent/AU2015359306B2/en active Active
- 2015-12-10 KR KR1020197018384A patent/KR20190077131A/ko not_active Ceased
- 2015-12-10 KR KR1020217030568A patent/KR20210122315A/ko not_active Ceased
- 2015-12-10 MX MX2017007651A patent/MX382489B/es unknown
- 2015-12-10 CA CA2964616A patent/CA2964616C/fr active Active
- 2015-12-10 PL PL15808184.4T patent/PL3229794T3/pl unknown
- 2015-12-10 SG SG11201704569SA patent/SG11201704569SA/en unknown
- 2015-12-10 WO PCT/EP2015/079311 patent/WO2016092042A1/fr not_active Ceased
- 2015-12-10 CN CN201580067625.2A patent/CN106999462B/zh active Active
- 2015-12-10 SM SM20250469T patent/SMT202500469T1/it unknown
-
2017
- 2017-05-09 SA SA517381489A patent/SA517381489B1/ar unknown
- 2017-06-06 IL IL252701A patent/IL252701B/en unknown
- 2017-06-07 PH PH12017501060A patent/PH12017501060B1/en unknown
- 2017-06-09 CL CL2017001479A patent/CL2017001479A1/es unknown
-
2018
- 2018-09-20 JP JP2018176173A patent/JP6846392B2/ja active Active
-
2019
- 2019-02-15 US US16/277,829 patent/US11026927B2/en active Active
-
2020
- 2020-12-23 JP JP2020213525A patent/JP7033642B2/ja active Active
-
2021
- 2021-05-20 US US17/325,912 patent/US11672783B2/en active Active
- 2021-12-12 IL IL288907A patent/IL288907A/en unknown
-
2022
- 2022-05-10 CY CY2022011C patent/CY2022011I2/el unknown
-
2023
- 2023-05-11 US US18/315,954 patent/US12409167B2/en active Active
-
2024
- 2024-01-02 US US18/401,886 patent/US20240131009A1/en not_active Abandoned
-
2025
- 2025-08-15 US US19/301,469 patent/US20250375426A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4620526A3 (fr) | Combinaison pharmaceutique comprenant du ponesimod et son utilisation dans le traitement de la sclérose en plaque | |
| UA124347C2 (uk) | Циклічна динуклеотидна сполука | |
| CN110869028A8 (zh) | 治疗猫冠状病毒感染的方法 | |
| ZA202006378B (en) | N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof | |
| MX2022010831A (es) | Formulaciones inyectables de liberacion extendida que comprenden un agente activo de isoxazolina, metodos y usos de las mismas. | |
| MX2020009010A (es) | Formulaciones inyectables de larga duracion que comprenden un agente activo de isoxazolina, metodos y usos de las mismas. | |
| MX2017010287A (es) | Composiciones farmaceuticas que comprenden n-(3,5-dimetoxifenil)-n '-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il)quinoxalin-6-il]eta no-1,2-diamina. | |
| CL2008002161A1 (es) | Compuestos derivados de pirazol de fórmula (i); procedimiento de preparación; composición farmacéutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad oclusiva de arterias, angina inestable, paro cardíaco, isquemia, cardiomiopatía, enfermedad de crohn, esclerosis múltiple, dolor neuropático. | |
| TN2016000230A1 (en) | Orally disintegrating solid dosage unit containing an estetrol component. | |
| EP4306113A3 (fr) | Composition pharmaceutique pour administration orale comprenant un dérivé d'aminopyrimidine ou son sel | |
| EP3789040A4 (fr) | Agent préventif et/ou thérapeutique pour maladie auto-immune comprenant un composé ayant une activité inhibitrice de btk en tant que principe actif | |
| IL281353A (en) | Pharmaceutical composition for preventing or treating nonalcoholic fatty liver disease, containing gpr119 ligand as active ingredient | |
| EP3999043A4 (fr) | Préparation d'ingrédients actifs lipophiles | |
| EA200501697A1 (ru) | Дозируемая форма, содержащая пантопразол в качестве активного ингредиента | |
| EP3388446A4 (fr) | Peptide amélioré inhibiteur de l'angiogenèse et composition pour prévenir et traiter une maladie associée à l'angiogenèse le comprenant en tant que principe actif | |
| EA201990550A1 (ru) | Офтальмологический препарат, включающий азоловое соединение | |
| EA201890896A1 (ru) | Твердый препарат для перорального применения, содержащий аморфный солифенацин, и способ его получения | |
| EP4285910A4 (fr) | Composition pharmaceutique pour le traitement d'une neuro-inflammation, comprenant de l'éleuthéroside b en tant que principe actif | |
| EA202190317A1 (ru) | Лекарственный препарат для наружного применения | |
| DE602005007485D1 (de) | Medikament zur behandlung von pilzinfektionen; insbesondere aspergillose | |
| EP3908265C0 (fr) | Composition pharmaceutique de type gel pour traiter/prevenir une infection | |
| KR102393125B9 (ko) | 켐페라이드를 유효성분으로 포함하고 오토파지 유도 활성을 갖는 단백질 형태이상 질환의 예방 또는 치료용 조성물 | |
| RU2024132887A (ru) | Полициклические соединения и способы целенаправленной деградации полипептидов быстро ускоренной фибросаркомы | |
| RU2446158C9 (ru) | Замещенные изоиндолы в качестве ингибиторов васе и их применение | |
| TR201914037A2 (tr) | Alantolacton etken maddesi̇ni̇n multi̇ple sklerozi̇s hastaliğinda i̇laç adayi olarak kullanilmasi |